

LIDODERM (lidocaine patch 5%)

**GPI CODING:**

908500600059\*\*

**DESCRIPTION:**

Lidocaine 5% patches are FDA-approved for the relief of pain associated with postherpetic neuralgia (PHN) only. Lidocaine is an amide-type local anesthetic agent whose neuronal membrane stabilizing effect produces a local analgesic effect when applied transdermally. The lidocaine penetration into intact skin is adequate to produce an analgesic effect, but less than the amount needed to produce a complete sensory block.

**APPROVAL DURATION:**

Approval duration: 1 year

**CRITERIA FOR LIDODERM**

- I. Patient has a diagnosis of post-herpetic neuralgia **AND**
- II. Patient has tried and failed at least one of the following medications:
  - A. Gabapentin
  - B. Carbamazepine
  - C. A tricyclic antidepressant
  - D. Lyrica
  - E. Cymbalta